Shimadzu launches amyloid mass spectrometry service

2022 07 11 16 26 9131 Shimadzu Rsna 2019 400

Shimadzu has announced the commercialization of its Amyloid Mass Spectrometry (MS) Service for the early detection of amyloid-positive individuals.

The new approach predicts abnormal amyloid-beta concentration, which can be an indicator of amyloid pathology in the brain, the firm said.

By enabling the reliable characterization of amyloid pathology in the brain, the blood-based method can assist in the development of pharmaceutical treatments for Alzheimer's disease.

Furthermore, the analysis is opening the door for new advances in research, identifying suitable candidates for clinical trials, and assisting pharmaceutical companies in their testing of candidate drugs, the firm said, adding that the method is suitable for large-scale deployment.

Spinal fluid tests may aid PET scans of Alzheimer's disease
2022 03 02 20 27 6315 2022 03 04 Tau Biomarkers 400
Page 1 of 2
Next Page